These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38492812)

  • 1. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.
    Tchelebi LT; Segovia D; Smith K; Shi Q; Fitzgerald TJ; Chuong MD; Zemla TJ; O'Reilly EM; Meyerhardt JA; Koay EJ; Lowenstein J; Shergill A; Katz MHG; Herman JM
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):111-119. PubMed ID: 38492812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM
    JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
    Katz MHG; Ou FS; Herman JM; Ahmad SA; Wolpin B; Marsh R; Behr S; Shi Q; Chuong M; Schwartz LH; Frankel W; Collisson E; Koay EJ; Hubbard JM; Leenstra JL; Meyerhardt J; O'Reilly E;
    BMC Cancer; 2017 Jul; 17(1):505. PubMed ID: 28750659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).
    Snyder RA; Zemla TJ; Shi Q; Segovia D; Ahmad SA; O'Reilly EM; Herman JM; Katz MHG
    Ann Surg Oncol; 2024 Oct; 31(10):7033-7042. PubMed ID: 39008208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
    Barrord M; Ahmad S; Patel S; Olowokure O; Sussman J; Smith M; Poreddy S; Esslinger H; Latif T; Choe K; Kharofa J
    Pancreas; 2020 Aug; 49(7):941-946. PubMed ID: 32658077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
    J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
    Cecchini M; Salem RR; Robert M; Czerniak S; Blaha O; Zelterman D; Rajaei M; Townsend JP; Cai G; Chowdhury S; Yugawa D; Tseng R; Mejia Arbelaez C; Jiao J; Shroyer K; Thumar J; Kortmansky J; Zaheer W; Fischbach N; Persico J; Stein S; Khan SA; Cha C; Billingsley KG; Kunstman JW; Johung KL; Wiess C; Muzumdar MD; Spickard E; Aushev VN; Laliotis G; Jurdi A; Liu MC; Escobar-Hoyos L; Lacy J
    JAMA Oncol; 2024 Aug; 10(8):1027-1035. PubMed ID: 38900452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
    van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
    Van Laethem JL; Borbath I; Prenen H; Geboes KP; Lambert A; Mitry E; Cassier PA; Blanc JF; Pilla L; Batlle JF; Garrote MR; Pazo-Cid RA; Gallego I; Smith KE; Ellmark P; Pico de Coaña Y; Ambarkhane SV; Macarulla T
    Lancet Oncol; 2024 Jul; 25(7):853-864. PubMed ID: 38834087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH; Shi Q; Ahmad SA; Herman JM; Marsh Rde W; Collisson E; Schwartz L; Frankel W; Martin R; Conway W; Truty M; Kindler H; Lowy AM; Bekaii-Saab T; Philip P; Talamonti M; Cardin D; LoConte N; Shen P; Hoffman JP; Venook AP
    JAMA Surg; 2016 Aug; 151(8):e161137. PubMed ID: 27275632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.
    Cloyd JM; Colby S; Guthrie KA; Lowy AM; Chiorean EG; Philip P; Sohal D; Ahmad S
    J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38688309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Yoon H; Shin Y; Ryoo BY; Jeong H; Park I; Seo DW; Lee SS; Park DH; Song TJ; Oh D; Hwang DW; Lee JH; Song KB; Park Y; Kwak BJ; Hong SM; Park JH; Kim SC; Kim KP; Yoo C
    Pancreatology; 2024 May; 24(3):424-430. PubMed ID: 38395676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.